Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 316

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 316
---
 progression or treating Pre-MCI or MCI and a method for determining the effectiveness of
a pre-MCI or MCI treatment in a subject, which is set to expire on April 18, 2032. In addition, foreign counterparts to the U.S. patents
have been granted in Australia, China (2), Switzerland, Germany, France, United Kingdom, Ireland, and Japan.

On August 24, 2021, the
USPTO issued to DiamiR U.S. Patent No. 11,098,362, entitled “Methods of using miRNAs from bodily fluids for detection and monitoring
of Parkinson’s disease (PD)”. The patent, which is set to expire on November 17, 2034, claims a method developed by DiamiR
for monitoring the effect of a treatment on development of PD and a method for identifying a compound useful for slowing down the progression
or treating PD in a subject who had been previously diagnosed with PD. In addition, foreign counterparts to the U.S. patent
have been granted in Canada, China, Switzerland, Germany, Spain, France, United Kingdom, Ireland, Italy and Japan.

On September 22, 2020,
the USPTO issued to DiamiR U.S. Patent No. 10,781,487, entitled “MiRNA-Based Methods for Detecting and Monitoring Aging”.
The patent, which is set to expire on July 24, 2038, claims a method developed by DiamiR for monitoring the rate of progression of
brain aging in a subject and a method for monitoring the effect of a treatment on progression of brain aging.

On October 19, 2021, the
USPTO issued to DiamiR U.S. Patent No. 11,149,313, entitled, “Methods of Using MiRNAs from Bodily Fluids for Detection and
Differentiation of Neurodegenerative Diseases”. The patent, which is set to expire on April 9, 2037, claims a method developed
by DiamiR for detecting a neurodegenerative disorder (ND) in a subject, wherein the ND is frontotemporal dementia (FTD) or amyotrophic
lateral sclerosis (ALS) (and further differentiating between FTD or ALS and other neurodegenerative disorders) as well as a method for
monitoring changes in development of FTD or ALS in a subject and a method for monitoring the effect of a therapeutic agent on development